Chondroprotective Effects of Bone Marrow Mesenchymal Stem Cell-derived Exosomes in Osteoarthritis
Overview
Biology
Endocrinology
Affiliations
Chondrocyte ferroptosis constitutes a major cause of the development of osteoarthritis (OA). Bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exos) have a protective role against ferroptosis in various diseases. Hence, we aimed to determine whether BMSC-Exos alleviated chondrocyte ferroptosis and its effect on OA, and to dissect out the possible mechanisms. An OA rat chondrocyte model was established by interleukin-1β (IL-1β) exposure, and treated with BMSC-Exos/ferroptosis inhibitor Ferrostatin-1. Cell viability/ferroptosis-related index levels [reactive oxygen species (ROS)/malondialdehyde (MDA)/glutathione (GSH)]/cell death/ACSL4 mRNA and protein levels and METTL3 levels were assessed by MTT/kits/immunohistochemical method and TUNEL staining/RT-qPCR and Western blot. METTL3/ACSL4 were overexpressed in rat chondrocytes to evaluate their role in BMSC-Exo-produced repression on chondrocyte ferroptosis. Bioinformatics website predicted the presence of m6A modification sites on ACSL4 mRNA, with the m6A level enriched on it assessed by MeRIP/RT-qPCR. ACSL4 mRNA stability was detected by actinomycin D assay. A surgical destabilized medial meniscus rat OA model was also established, followed by injection with BMSC-Exos to verify their function. IL-1β stimulation in rat chondrocytes inhibited cell viability, elevated Fe/ROS/MDA levels, declined GSH levels and increased TUNEL positive cell number and ACSL4 level, which were neutralized by BMSC-Exos. BMSC-Exos limited chondrocyte ferroptosis by down-regulating METTL3, with the effect abrogated by METTL3 overexpression. METTL3 regulated the m6A modification of ACSL4 mRNA, increasing ACSL4 mRNA stability and ACSL4 expression. BMSC-Exos reduced chondrocyte ferroptosis and prevented OA progression via disruption of the METTL3-m6A-ACSL4 axis. BMSC-Exos might exert a chondroprotective effect by attenuating chondrocyte ferroptosis and alleviate OA progression.
Xiao D, Zhang D, Qu Y, Su X J Cell Mol Med. 2025; 29(5):e70483.
PMID: 40052548 PMC: 11886889. DOI: 10.1111/jcmm.70483.
The Role of mRNA Modifications in Bone Diseases.
Li Z, Meng K, Lan S, Ren Z, Lai Z, Ao X Int J Biol Sci. 2025; 21(3):1065-1080.
PMID: 39897026 PMC: 11781163. DOI: 10.7150/ijbs.104460.
Exosomes of stem cells: a potential frontier in the treatment of osteoarthritis.
Wang X, Xu L, Wu Z, Lou L, Xia C, Miao H Precis Clin Med. 2025; 8(1):pbae032.
PMID: 39781279 PMC: 11705996. DOI: 10.1093/pcmedi/pbae032.
Ferroptosis in Osteoarthritis: Towards Novel Therapeutic Strategy.
Zhang Y, Li J, Liu J, Gao Y, Li K, Zhao X Cell Prolif. 2024; 58(3):e13779.
PMID: 39624950 PMC: 11882765. DOI: 10.1111/cpr.13779.
Chu C, Lee R, Wu W, Chen I, Yeh K, Wang C Biomedicines. 2024; 12(11).
PMID: 39595044 PMC: 11591758. DOI: 10.3390/biomedicines12112478.